TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urinary glucose excretion (UGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Infarct size at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory flow after 50% of FVC (FEF(50))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Initial quality of the airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TVmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P(leak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed intravascular TG lipolysis as a predictor of severe angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cause of dizziness identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day rate of death/stroke
Endpoint domain: Mortality/survival
Primary endpoint: Port infection within 30 days of placement
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in percentage of uncovered struts between BESs and SESs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participation in unstructured play activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Laboratory-confirmed respiratory viral infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients remaining abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe adverse effects leading to trial termination
Endpoint domain: Adverse events/effects
Primary endpoint: Ovulation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anovulation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Luteal Es levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: modified Rankin scale score at day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of LUT discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores (numeric rating scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal wall sensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apoptosis Index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical response (> 50% ALT reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Rate of sustained responders at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: PaO2 levels 4 hours after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum muscle enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aversive inner tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge to commit self-injurious behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy food choices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate on HAMD and PHQ-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of secondary leukaemia (SL)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of secondary malignancies (SM)
Endpoint domain: Mortality/survival
Primary endpoint: Left Ventricular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative Wall Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Reduction in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate (HR) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPO2 % decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: Child anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental posttraumatic intrusion symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall posttraumatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recrudescence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Corneal clarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Energy utilization (EPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RASE score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of fall injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower-limb strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average cost per average required distance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average distance flown per distance required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental cost-utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: quality-adjusted life-year (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AF-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of smoking during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of necrosis related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach a subtoxic level of phenytoin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lobene stain composite mean scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent (area) average scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity average scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success of treated teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic success of treated teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid Intima-Media Thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed venous thromboembolic events
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in the use of ultrasonography
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence rates of endometriosis
Endpoint domain: Mortality/survival
Primary endpoint: Selection of healthier food choices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activity rate during training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average hemoglobin level on discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to run
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: discomfort during anaesthesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: discomfort during scope insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: comfortable gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ephedrine consumption per hypotension case
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Developing diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in log10 HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical data (plasma potassium and urea levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Credibility of antidepressant medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bout-related MVPA minutes/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: achievement of public health guideline (≥150 bout-related MVPA minutes/week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall analysis segment plaque + media volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No reflow incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in patients with trigeminal neuralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole-body BMD reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Reperfusion rate (TIMI 2 + 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to TIMI 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stage of action to test for radon and air nicotine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peak vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year local control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of meperidine used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of myoclonus
Endpoint domain: Adverse events/effects
Primary endpoint: femoral tunnel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: tunnel widening percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: signal-noise quotient value of the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: new acquisition of pneumococci susceptible to multiple antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: overall treatment time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postextubation cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hamilton Rating Scale for Anxiety (HAM-A) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders (Clinical Global Impressions-Improvement scale score <= 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction of UA to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Significant increase in eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean reduction in plasma renin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Skeletal transverse diameters expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in skin bacterial colony counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants receiving treatment for depression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants receiving treatment for AUD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EQ-5D-5L improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-VAS improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adjusted cost of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Painful voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary disorder presence and identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total comet score (TCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Success rate of stone fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in VAS for back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in segmental range of motion at surgical levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean recovery of total lumbar lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PoCE (Patient-oriented composite endpoint)
Endpoint domain: Mortality/survival
Primary endpoint: MACE (Major adverse cardiac events)
Endpoint domain: Mortality/survival
Primary endpoint: TVF (Target vessel failure)
Endpoint domain: Mortality/survival
Primary endpoint: Probability of successful weaning by the fifth day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MV weaning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for assistance during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: surface inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of antibodies to hepatitis B e antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 8-feet walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk performance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response (≥ 50% reduction in symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exclusive breast feeding at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of any breast feeding up to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pelvic pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of vaginal dryness and dyspareunia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in intermediate and superficial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median duration of coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: median duration of rhonchi on lung auscultation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Non-hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet recovery duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Toxic deaths
Endpoint domain: Mortality/survival
Primary endpoint: Low Birth Weight (LBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preterm Delivery (PTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Occurrence of stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intrahepatic HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unsatisfactory outcome
Endpoint domain: Mortality/survival
Primary endpoint: Ocular redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Dysphagia-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ARAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Needed to Treat (NNT) for severe carotid stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number Needed to Treat (NNT) for moderate carotid stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of locomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ease of fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in high-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in biomarkers of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodyweight increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of lymph node involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Likelihood of immediate axillary clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Likelihood of delayed axillary clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: complete abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month sustained abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse drug reaction incidence
Endpoint domain: Adverse events/effects
Primary endpoint: duration of implementations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in clinical symptoms (dyspnoea, wheezing, cough, expectoration, disability, sleep disturbances)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional response to LSS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak serum concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration‐time curve (AUC(0‐∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time above minimal inhibitory concentration (T > MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR)
Endpoint domain: Mortality/survival
Primary endpoint: indices of respiratory effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma prothrombin fragment 1+2 (F(1+2)) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombin-antithrombin (TAT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of PDPH
Endpoint domain: Adverse events/effects
Primary endpoint: Total error number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical significance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) scores at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel function recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptoms of viral infectious diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Contrast-to-noise ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in motor functions of upper limb extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of performed movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in the FPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma concentration (C(max)) of HCTZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean exposure (AUC(0‐48 h)) of HCTZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of HCTZ with BENA and VAL
Endpoint domain: Adverse events/effects
Primary endpoint: 8-year cumulative mortality for colorectal cancer
Endpoint domain: Mortality/survival